Metabolic reprogramming in the tumor microenvironment shapes immune function and therapy resistance, offering insights into ...

Spatial transcriptomics provides a unique perspective on the genes that cells express and where those cells are located. However, the rapid growth of the technology has come at the cost of ...

(MEMPHIS, Tenn. – December 3, 2025) Spatial transcriptomics provides a unique perspective on the genes that cells express and where those cells are located. However, the rapid growth of the technology ...

Single-cell RNA transcriptomics allows researchers to broadly profile the gene expression of individual cells in a particular tissue. This technique has allowed researchers to identify new subsets of ...

“Illumina’s…presentations and product descriptions revealed a workflow that infringed on the ‘607, ‘138, ‘505, and ‘487 patents, 10x Genomics and Prognosys Biosciences argued.” On October 21, 10x ...

Biological systems are inherently three-dimensional—tissues form intricate layers, networks, and architectures where cells interact in ways that extend far beyond a flat plane. To capture the true ...

Adoptive therapy with T cells engineered to be specific for tumor targets holds significant potential for treating solid tumors, but suppressive signals within the tumor microenvironment (TME) can ...

The treatment of tumors remains one of the most challenging issues in modern medicine. For a long time, surgical intervention and radiochemotherapy were the primary methods employed to combat tumors; ...

TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, ...

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...

Conventional transcriptomic techniques have revealed much about gene expression at the population and single-cell level—but they overlook one crucial factor: spatial context. In musculoskeletal ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. It’s more than just existing PD-1/L1 players ...